Introduction {#section1-0963689717715822}
============

Spinal cord injury (SCI) is one of the most debilitating neurological diseases affecting the motor, sensory, and the autonomic systems.^[@bibr1-0963689717715822],[@bibr2-0963689717715822]^ Because the pathophysiology mechanism of SCI is not fully reported, a comprehensive approach is important to study SCI pathogenesis.

After SCI, pathophysiological events may occur, including acute, subacute, and chronic phases. The acute phase happens immediately after injury and primary damage leads to immediate physical and biochemical cellular alteration such as hemorrhage, ischemia, and hypoxia.^[@bibr3-0963689717715822],[@bibr4-0963689717715822]^ Subsequently, subacute phase, occurring over time after SCI, leads to further damage SCI results in a rapid and extensive oxidative stress reaction, which causes oxidative death of the spinal cord neurons and reduces spinal cord blood flow that leads to edema and inflammatory responses at subacute phase.^[@bibr5-0963689717715822],[@bibr6-0963689717715822]^ Moreover, SCI results in apoptosis, which severely affect neurons, oligodendrocyte, microglia, and, perhaps, astrocytes, as well as astrogliosis.^[@bibr6-0963689717715822],[@bibr7-0963689717715822]^ Furthermore, the chronic phase of SCI consists of many incidents, such as white matter demyelination, gray matter dissolution, connective tissue deposition, and reactive gliosis. These events lead to glial scar formation.^[@bibr6-0963689717715822]^

Additionally, pathophysiological mechanisms of SCI have been further related to brain injury such as cerebral ischemia and subarachnoid hemorrhage.^[@bibr8-0963689717715822][@bibr9-0963689717715822]--[@bibr10-0963689717715822]^ Recent studies have shown that SCI causes brain inflammation, progression of nerve cell loss, as well as loss of brain functions such as cognition and could lead to depression.^[@bibr11-0963689717715822],[@bibr12-0963689717715822]^ Several studies already have investigated the alteration of gene expression response in the brain after SCI.^[@bibr13-0963689717715822][@bibr14-0963689717715822][@bibr15-0963689717715822][@bibr16-0963689717715822][@bibr17-0963689717715822][@bibr18-0963689717715822]--[@bibr19-0963689717715822]^ Brain-derived neurotrophic factor (BDNF), glial cell line--derived neurotrophic factor, and histone deacetylase 1 (HDAC1) may play an important role in the brain reorganization after SCI;^[@bibr20-0963689717715822],[@bibr21-0963689717715822]^ however, only little is known and further studies will be needed.

In this study, we investigated the progression of the brain injury after SCI at acute phase (3 h post-injury) and subacute phase (2 wk post-injury) by gene expression patterns using transcriptome analysis. We performed and confirmed differentially expressed genes (DEGs) profiling to identify enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that will enable the demonstration of the brain injury after SCI pathophysiological mechanism at acute phase and subacute phase. Some candidate genes belonged to enriched KEGG pathways and were considered to show significant roles in the brain after SCI. These results provide a better understanding of association between brain injury and SCI.

Materials and Methods {#section2-0963689717715822}
=====================

Animals {#section3-0963689717715822}
-------

For all animal experiments, CD-1 (ICR) mice were housed in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. The experimental procedure was approved by the Institutional Animal Care and Use Committee (IACUC) of Yonsei University Health System.

Male mice of age 7 wk (Orient bio, Gyeonggi-do, South Korea) were used and were randomly classified into 3 groups: sham control brain group (*n* = 3), 3 h post-SCI brain group (*n* = 3), and 2 wk post-SCI brain group (*n* = 3).

Spinal Cord Contusion {#section4-0963689717715822}
---------------------

Animals were anesthetized with a mixture of ketamine (100 mg/kg, intraperitoneal, Yuhan, Seoul, Korea) and xylazine (10 mg/kg, intraperitoneal), and absence of blink and withdrawal reflexes were ensured. Body temperature was maintained at 37 °C in a hypoxic chamber. Mice received a dorsal laminectomy at the 9th thoracic vertebral (T9) level to expose the spinal cord and then a moderate T9 contusive injury by the Infinite Horizons device (Precision Systems and Instrumentation, Lexington, NY, USA) to moderate force of 70 kdyn. The sham control mice received only a dorsal laminectomy without contusive injury. Afterward, the wound was sutured in layers. Post-operative care consisted of manual bladder expression twice a day until automatic voiding returned spontaneously, which is generally around 7 days. After 3 h or 2 wk following SCI, the mice were anesthetized again with ketamine and xylazine and perfused transcardially with normal saline for isolation of injured brains and spinal cords. These tissues were frozen at −70 °C and processed for RNA isolation.

RNA Preparation {#section5-0963689717715822}
---------------

Total RNA was prepared from the bilateral cerebrum after SCI using the TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturers' protocols. For quality control, RNA quality and quantity were evaluated by 1% agarose gel electrophoresis and the optical density (OD) 260/280 ratio was confirmed with a Nanodrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA).

RNA Sequencing and Transcriptome Data Analysis {#section6-0963689717715822}
----------------------------------------------

RNA sequencing was performed by Macrogen, Inc. (Seoul, Korea). The messenger RNA (mRNA) was transcribed into a library of templates. This successive cluster generation using reagents was provided by the Illumina® TruSeq™ (Illumina, San Diego, CA, USA) RNA Sample Preparation Kit.^[@bibr22-0963689717715822][@bibr23-0963689717715822][@bibr24-0963689717715822]--[@bibr25-0963689717715822]^ We performed the transcriptome analysis by the following procedures: RNA-seq experiment and data handling procedure. The detailed procedures of RNA-seq experiment are performed following the manufacturer's instruction. Firstly, there are 8 steps in TruSeq mRNA library construction: purify and fragment mRNA, synthesize first strand complementary DNA (cDNA), synthesize second strand cDNA, perform end repair, adenylate the 3′ end of the DNA fragments, ligate adapters, enrich DNA fragments, and enrich library validation. Purifying step for the poly-A-containing mRNA molecules was carried out using magnetic beads, which attached poly-T oligo. After that, the cleaved RNA fragments are copied into first strand cDNA using reverse transcriptase and random primers. Next, synthesize second strand cDNA process removes the RNA template and synthesizes a replaced strand to generate double-stranded (DS) cDNA with DNA polymerase I and Ribonuclease H (RNaseH). The end repair process converts the overhangs resulting from fragmentation into blunt ends, using an end repair mix (End Repair Mix \[ERP\]). Next, "A" nucleotide is added to the 3′ ends of the blunt fragments to prevent them from ligating to one another during the adapter ligation reaction. In the process of ligation of adapters, multiple indexing adapters ligate to the ends of the ds cDNA, preparing them for hybridization into a flow cell. In the enriched DNA fragments process, we performed polymerase chain reaction (PCR) to get enriched cDNA library. Finally, enriched library validation was performed for quality control analysis of the sample library and quantification of the DNA library templates.^[@bibr26-0963689717715822]^

The second procedure of RNA sequencing is clustering and sequencing using the Illumina. The Illumina utilizes a unique "bridged" amplification reaction that occurs on the surface of the flow cell. A flow cell with millions of unique clusters is loaded into the HiSeq 2000 for automated cycles of extension and imaging. Solexa's sequencing-by-synthesis utilizes 4 proprietary nucleotides possessing reversible fluorophore and termination properties.^[@bibr22-0963689717715822]^ Each sequencing cycle occurs in the presence of all 4 nucleotides, leading to higher accuracy than methods where only 1 nucleotide is present in the reaction mix at a time. The next procedure is data handling, which contains sequence quality check and data analysis. SolexaQA is a Perl-based software package that calculates quality statistics and creates visual representations of data quality from FASTQ files generated by Illumina second-generation sequencing technology. And then, Cufflinks assembles transcripts, estimates their abundances, and tests for differential expression and regulation in RNA-seq samples. It accepts reading of aligned RNA-seq and assembles the alignments into a parsimonious set of transcripts based on how many reads support each one, taking into account biases in the library preparation protocol. Transcripts with a fold change ≥\|1.5\| and *P* \< 0.05 were considered significant and were included in downstream analysis.

KEGG Pathway Analyses {#section7-0963689717715822}
---------------------

The lists of significant DEGs (fold change ≥ \|1.5\|) were submitted to the Database for Annotation, Visualization, and Integrated Discovery (DAVID v6.7; <http://david.abcc.ncifcrf.gov/>) for KEGG pathways analysis.^[@bibr27-0963689717715822][@bibr28-0963689717715822]--[@bibr29-0963689717715822]^

Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR) {#section8-0963689717715822}
--------------------------------------------------------------------------------

DEGs of interest were selected for the validation of transcriptome analysis results by qRT-PCR. Total RNA was reverse transcribed into cDNA using ReverTra Ace® qPCR RT Master Mix with genomic DNA Remover (Toyobo, Osaka, Japan) according to the manufacturer's instructions. The mRNA expression for genes of interest was profiled using qPCRBIO SyGreen Mix Hi-ROX (PCR Biosystems, London, UK) in a StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Data analysis was performed using the 2^−ΔΔCT^ method. Primers used for qRT-PCR are described in [Table 1](#table1-0963689717715822){ref-type="table"}.

###### 

Primers Used in qRT-PCR.

![](10.1177_0963689717715822-table1)

  Gene         Forward Primer (5′ → 3′)     Reverse Primer (5′ → 3′)        Gene        Forward Primer (5′ → 3′)         Reverse Primer (5′ → 3′)
  ------------ ---------------------------- ------------------------------- ----------- -------------------------------- --------------------------------
  *ATP6V0C*    GGG ATC ATC GCC ATC TAC GC   CAA CAC CAG CAT CTC CGA CG      *H2-L*      CGG TAC ATC TCT GTC GGC TAT      CTT GGC GAT CTG CGT GAT
  *COX7B*      AAA CGC ACT AAG CGC TCT CC   ACT CTG CCA ACA GGG GAC AT      *H2-T22*    AAA AGG GAA GGA GAG GCT GC       CTC CTC CCC ATT CAA CTG CC
  *TNFRSF25*   GAG CTG CCT AGG AGG GAG AG   AAC GGG CCA TAC CTC TTC TG      *LTα*       GAT CGT GCC TTT CTC CGA CA       AAA GAG CTG GAC CTC GTG TG
  *CCR5*       ACA CCC TGT TTC GCT GTA GG   TGC ATG GCC TGG TCT AGT CT      *H2-K1*     AAG CCC CTC ACC CTG AGA TG       GAG GCT GAG AGA AAA CGC ACA
  *CCR6*       CCC TCA CAA CAT GGT CCT CC   AAA CGC ATA CAA CAC GGG G       *HSPB1*     TCA CCC GGA AAT ACA CGC TC       GGC CTC GAA AGT AAC CGG AA
  *HGF*        CAC CTC CTC CTG CTT CAT GT   GCC CCT GTT CCT GAT ACA CC      *JMJD7*     AAG ATG CCT GAT GCC GTG AA       CTG GTA GGT TGC TGG TGT GT
  *IL12RB1*    TGG GAG TCA GAG TGG CTC GT   TGG GAG TCA GAG TGG CTC GT      *FGFR2*     GAT CAC GGC TTC CCC AGA TT       CTC GGC CGA AAC TGT TAC CT
  *CCL17*      ACT TCA AAG GGG CCA TTC CT   CAT GGC CTT GGG TTT TTC ACC     *RASGRP3*   AAA ATC CCC ATC CTT GGC GT       AGT GGT GAG AGG CAT TCT GC
  *GNG11*      CAC ATC GAG GAT CTG CCG GA   CAG CTG CCC TTT TCT TTG AAG G   *DDIT3*     GTC ACA CGC ACA TCC CAA AG       CAC TTT CCG CTC GTT CTC CT
  *NFKBIA*     ATC CTG ACC TGG TTT CGC TC   CTC ATC CTC GCT CTC GGG TA      *DUSP5*     TCG CCT ACA GAC CAG CCT AT       CGG GGA TCC ACT TGT AGT GT
  *HSPA1AB*    TGA ACT ACA AGG GCG AGA GC   CCG CTG AGA GTC GTT GAA GT      *MAP3K6*    CCC TTC GTG AGG ATG TTT TCC      CAG CCT GTA CTA GCC CAT CG
  *HSPA5*      ATT GGA GGT GGG CAA ACC AA   TCG CTG GGC ATC ATT GAA GT      *PLA2G3*    GGA TCT CCT GGG TAC CAC CT       ATC CCT GAA ATG GAG TCG GC
  *CALR*       CGG GGA CCT GGA GAA GGA TA   CCA AAC CAC TCG GAA ACA GC      *CX3CR1*    CAC CAT TAG TCT GGG CGT CT       GCG GAA GTA GCA AAA GCT CA
  *PDIA3*      CGG GGA CCT GGA GAA GGA TA   GGT AGC CAC TGA CCC CAT AC      *GAPDH*     CAT CAC TGC CAC CCA GAA GAC TG   ATG CCA GTG AGC TTC CCG TTC AG

Abbreviations: qRT-PCR, Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction; *ATP6V0C*, ATPase, H+ transporting V0 subunit C; *COX7B*, Cytochrome c oxidase subunit VIIb; *TNFRSF25*, Tumor necrosis factor receptor superfamily member 25 isoform 1 precursor; *CCR5*, Chemokine (C-C motif) receptor 5; *CCR6*, Chemokine (C-C motif) receptor 6; *HGF*, Hepatocyte growth factor isoform 3 preproprotein; *IL12RB1*, Interleukin 12 receptor, beta 1; *CCL17*, Chemokine (C-C motif) ligand 17; *GNG11*, Guanine nucleotide binding protein (G protein), gamma 11; *NFKBIA*, Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha; *HSPA1AB*, Heat shock protein 1AB; *HSPA5*, Heat shock protein 5; *CALR*, Calreticulin; *PDIA3*, Protein disulfide isomerase associated 3; *H2-L*, Histocompatibility 2, D region locus L; *H2-T22*, Histocompatibility 2, T region locus 22; LTα, Lymphotoxin A; *H2-K1*, Histocompatibility 2, K1, K region; *HSPB1*, Heat shock protein 1; *JMJD7*, Jumonji domain containing 7; *FGFR2*, Fibroblast growth factor receptor 2; *RASGRP3*, RAS, guanyl releasing protein 3; *DDIT3*, DNA damage-inducible transcript 3 protein; *DUSP5*, Dual specificity phosphatase 5; *MAP3K6*, Mitogen-activated protein kinase kinase kinase 6; *PLA2G3*, Phospholipase A2, group III; *CX3CR1*, Chemokine (C-X3-C motif) receptor 1; *GAPDH*, glyceraldehyde-3-phosphate desidrogenase.

Western Blot Analysis {#section9-0963689717715822}
---------------------

To assess Cytochrome C Oxidase Subunit 7B (COX7B), TNF Receptor Superfamily Member 25 (TNFRSF25), Heat Shock 70 KDa Protein 1A/1B (HSPA1AB), Heat Shock 70kD Protein 5 (HSPA5), and NF-Kappa-B Inhibitor Alpha (NFKBIA), the brain samples were homogenized and dissolved in radioimmunoprecipitation assay buffer (RIPA) buffer (Thermo Fisher Scientific, Rockford, IL, USA) with protease inhibitors (Abcam, Cambridge, UK). Total proteins were quantified using *bicinchoninic acid assay* (*BCA* *assay*)™ Protein Assay Kit (Thermo Fisher Scientific). The samples were denatured and separated by 4% to 12% Bis-Tris gels in 1× NuPage MES SDS running buffer (Invitrogen, Eugene, OR, USA). Bands were transferred onto a polyvinylidene difluoride (PVDF) (Invitrogen) in 20% (vol/vol) methanol in NuPage Transfer Buffer (Invitrogen) at 4 °C. Membranes were blocked and then incubated overnight at 4 °C with the following antibodies: *COX7B* (1:1,000, Abcam), *TNFRSF25* (1:1,000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), *HSPA1AB* (1:1,000, Santa Cruz Biotechnology), *HSPA5* (1:1,000, Santa Cruz Biotechnology), *NFKBIA* (1:1,000, Santa Cruz Biotechnology), and *Actin* (1:3,000, Santa Cruz Biotechnology). The next day, the blots were washed 3 times with tris-buffered saline (TBS) (Biosesang, Gyeonggi-do, Korea) plus 0.1% Tween 20 (Bio-Rad, Hercules, CA, USA) and incubated for 1 h with horseradish peroxidase (HRP)--conjugated secondary antibodies (1:4,000; Santa Cruz) at room temperature. After being washed 3 times with TBS plus 0.1% Tween 20, the protein was visualized with an enhanced chemiluminescence (ECL) detection system (Amersham Pharmacia Biotech, Little Chalfont, UK).

Statistical Analysis {#section10-0963689717715822}
--------------------

All results were expressed as means ± standard error of the mean (SEM). Statistical analyses were conducted using the premier vendor for Statistical Package for Social Sciences (SPSS) Version 23.0 (SPSS Inc, Chicago, IL, USA). Nonparametric statistical analysis such as Mann--Whitney *U* test was used for the comparison of 2 groups. Student *t* test was used to confirm statistical results. Results with *P* value \< 0.05 was considered statistically significant.

Results {#section11-0963689717715822}
=======

Gene Expression Profile {#section12-0963689717715822}
-----------------------

Total RNA was prepared from samples obtained from the bilateral cerebrum after SCI. Next we performed transcriptome analysis by RNA sequencing in order to identify gene differentially expressed at different phases. Heat map profile of mRNA expression displaying differentially regulated transcripts is shown in [Fig. 1A](#fig1-0963689717715822){ref-type="fig"}. Color key and *z*-score show relative expression level of the samples. Red is maximum and green represents minimum expression levels of the samples.

![Gene expression profile by transcriptome analysis. (A) Heat map of the 2-way hierarchical clustering using *z*-score for normalized value. The color scheme is based on *z*-scores, with upregulation in red and downregulation in green. (B) Spinal cord injury (SCI) phases were classified into 2 phases: acute phase and subacute phase. Differentially expressed genes (DEGs) were identified at acute phase (3 h post-SCI) compared to sham control, at subacute phase (2 wk post-SCI) compared to sham control, or at subacute phase compared to acute phase. Bar graphs show the number of DEGs with fold change ≥ \|1.5\| at different phases (*P* \< 0.05). (C) Oxidative phosphorylation is an enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway at acute phase. (D) Cytokine--cytokine receptor interaction, chemokine signaling pathway, and antigen processing and presentation are enriched KEGG pathways at subacute phase. (E) Antigen processing and presentation, mitogen-activated protein kinase (MAPK) signaling pathway, and cytokine--cytokine receptor interaction are enriched KEGG pathways at subacute phase compared to acute phase.](10.1177_0963689717715822-fig1){#fig1-0963689717715822}

Upregulated and downregulated genes (1.5-fold) were counted and summarized in [Fig. 1B](#fig1-0963689717715822){ref-type="fig"}. We identified 78 DEGs, 50 DEGs were upregulated and 28 DEGs were downregulated, in the 3 h post-SCI brain compared to sham control brain. Furthermore, 383 DEGs, 201 upregulated DEGs and 182 downregulated DEGs, were identified in 2 wk post-SCI brain expression compared to sham control brain expression. Moreover, 316 DEGs---132 upregulated DEGs and 184 downregulated DEGs---were identified in 2 wk post-SCI brain expression compared to 3-h post-SCI brain.

Enriched KEGG Pathway Analysis {#section13-0963689717715822}
------------------------------

In order to analyze pathways, total DEGs were classified based on information regarding gene function using KEGG pathway database from DAVID. These results were statistically significant (*P* \< 0.05) and demonstrated in [Table 2](#table2-0963689717715822){ref-type="table"}.

###### 

The Enriched KEGG Pathways at Different Phases.

![](10.1177_0963689717715822-table2)

  Term                                                 Count   \%      *P* Value   Genes
  ---------------------------------------------------- ------- ------- ----------- -------------------------------------------------------------------------------------
  Acute phase compared to sham control                                             
   mmu00190: Oxidative phosphorylation                 3       4.688   0.049       *COX7B2*, *COX7B*, *ATP6V0C*
  Subacute phase compared to sham control                                          
   mmu04060: Cytokine--cytokine receptor interaction   11      2.967   0.010       *CCR6, IL12RB1, CCR5, GM13305, TNFRSF25, CX3CR1, CCL21A, HGF, GM1987, PRL, CCL17*
   mmu04062: Chemokine signaling pathway               9       2.374   0.019       *CCR6, CCR5, CX3CR1, CCL21A, NFKBIA, GNG11, FOXO3, GM1987, CCL17*
   mmu04612: Antigen processing and presentation       6       1.484   0.047       *H2-L, PDIA3, HSPA1A, HSPA1B, HSPA5, CALR*
  Subacute phase compared to acute phase                                           
   mmu04612: Antigen processing and presentation       7       2.083   0.010       *H2-K1, H2-T22, HSPA1A, H2-T23, HSPA1B, HSPA5, LTα*
   mmu04010: MAPK signaling pathway                    11      3.472   0.014       *DUSP5, FGFR2, MAP3K6, RASGRP3, JMJD7, FGF11, HSPB1, HSPA1A, HSPA1B, PLA2G3, DDIT3*
   mmu04060: Cytokine--cytokine receptor interaction   9       3.125   0.024       *CCL12, IL12RB1, CCR5, GM13305, TNFRSF25, CX3CR1, PRL, LTα, CCL17*

Abbreviations: These pathways are statistically significant (*P* \< 0.05). KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase; *COX7B2*, Cytochrome c oxidase subunit VIIb2; *ATP6V0C*, ATPase, H+ transporting V0 subunit C; *COX7B*, Cytochrome c oxidase subunit VIIb; *TNFRSF25*, Tumor necrosis factor receptor superfamily member 25 isoform 1 precursor; *CCR5*, Chemokine (C-C motif) receptor 5; *CCR6*, Chemokine (C-C motif) receptor 6; *HGF*, Hepatocyte growth factor isoform 3 preproprotein; *IL12RB1*, Interleukin 12 receptor, beta 1; *CCL17*, Chemokine (C-C motif) ligand 17; *GNG11*, Guanine nucleotide binding protein (G protein), gamma 11; *NFKBIA*, Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha; *HSPA1AB*, Heat shock protein 1AB; *HSPA5*, Heat shock protein 5; *CALR*, Calreticulin; *PDIA3*, Protein disulfide isomerase associated 3; *H2-L*, Histocompatibility 2, D region locus L; *H2-T22*, Histocompatibility 2, T region locus 22; LTα, Lymphotoxin A; *H2-K1*, Histocompatibility 2, K1, K region; *HSPB1*, Heat shock protein 1; *JMJD7*, Jumonji domain containing 7; *FGFR2*, Fibroblast growth factor receptor 2; *RASGRP3*, RAS, guanyl releasing protein 3; *DDIT3*, DNA damage-inducible transcript 3 protein; *DUSP5*, Dual specificity phosphatase 5; *MAP3K6*, Mitogen-activated protein kinase kinase kinase 6; *PLA2G3*, Phospholipase A2, group III; *CX3CR1*, Chemokine (C-X3-C motif) receptor 1; GM13305, Predicted gene 13305; *CCL21A*, Chemokine (C-C motif) ligand 21A (serine); GM1987, Predicted gene 1987; PRL, Prolactin; *FOXO3*, Forkhead box O3; H2-T23, Histocompatibility 2, T region locus 23; FGF11, Fibroblast growth factor 11 isoform 2; *CCL12*, Chemokine (C-C motif) ligand 12.

At acute phase, we observed enriched KEGG pathways including oxidative phosphorylation compared to sham control. At subacute phase, there was cytokine--cytokine receptor interaction, chemokine signaling pathway, and antigen processing and presentation compared to sham control. Compared to acute phase, enriched KEGG pathways such as antigen processing and presentation, mitogen-activated protein kinase (MAPK) signaling pathway, and cytokine--cytokine receptor interaction were altered in subacute phase. Each upregulated and downregulated genes was counted and summarized in [Fig. 1C to E](#fig1-0963689717715822){ref-type="fig"}.

Validation of Transcriptome Data Using qRT-PCR and Western Blot {#section14-0963689717715822}
---------------------------------------------------------------

To validate the altered gene expression (fold change ≥ \|1.5\|), we performed qRT-PCR and Western blot at different phases. To support the reliability and accuracy of the RNA-seq expression results, we first performed qRT-PCR, and Western blot was conducted for further validation. Each validated DEGs involved in enriched KEGG pathways was summarized in [Table 3](#table3-0963689717715822){ref-type="table"}.

###### 

Validated DEGs Involved in Enriched KEGG Pathways at Different Phases.

![](10.1177_0963689717715822-table3)

  Pathway                                    Gene Symbol   Gene Description                                                                      Fold Change
  ------------------------------------------ ------------- ------------------------------------------------------------------------------------- -------------
  Acute phase compared to sham control                                                                                                           
   Oxidative phosphorylation                 *ATP6V0C*     ATPase, H+ transporting V0 subunit C                                                  6.34
                                             *COX7B*       Cytochrome c oxidase subunit VIIb                                                     −1.59
  Subacute phase compared to sham control                                                                                                        
   Cytokine--cytokine receptor interaction   *TNFRSF25*    Tumor necrosis factor receptor superfamily member 25 isoform 1 precursor              2.7
                                             *CCR5*        Chemokine (C-C motif) receptor 5                                                      1.7
                                             *CCR6*        Chemokine (C-C motif) receptor 6                                                      1.6
                                             *HGF*         Hepatocyte growth factor isoform 3 preproprotein                                      −1.5
                                             *IL12RB1*     Interleukin 12 receptor, beta 1                                                       −1.6
                                             *CCL17*       Chemokine (C-C motif) ligand 17                                                       −2.0
   Chemokine signaling pathway               *GNG11*       Guanine nucleotide binding protein (G protein), gamma 11                              2.0
                                             *CCR5*        Chemokine (C-C motif) receptor 5                                                      1.7
                                             *CCR6*        Chemokine (C-C motif) receptor 6                                                      1.6
                                             *CCL17*       Chemokine (C-C motif) ligand 17                                                       −2.0
                                             *NFKBIA*      Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha   −2.1
   Antigen processing and presentation       *HSPA1AB*     Heat shock protein 1AB                                                                3.9
                                             *HSPA5*       Heat shock protein 5                                                                  2.4
                                             *CALR*        Calreticulin                                                                          1.6
                                             *PDIA3*       Protein disulfide isomerase associated 3                                              1.5
                                             *H2-L*        Histocompatibility 2, D region locus L                                                −1.8
  Subacute phase compared to acute phase                                                                                                         
   Antigen processing and presentation       *HSPA1AB*     Heat shock protein 1AB                                                                3.3
                                             *HSPA5*       Heat shock protein 5                                                                  2.1
                                             *H2-T22*      Histocompatibility 2, T region locus 22                                               −1.6
                                             *LTα*         Lymphotoxin A                                                                         −1.6
                                             *H2-K1*       Histocompatibility 2, K1, K region                                                    −1.7
   MAPK signaling pathway                    *HSPA1AB*     Heat shock protein 1AB                                                                3.3
                                             *HSPB1*       Heat shock protein 1                                                                  2.5
                                             *JMJD7*       Jumonji domain containing 7                                                           1.8
                                             *FGFR2*       Fibroblast growth factor receptor 2                                                   1.7
                                             *RASGRP3*     RAS, guanyl releasing protein 3                                                       1.6
                                             *DDIT3*       DNA damage-inducible transcript 3 protein                                             1.6
                                             *DUSP5*       Dual specificity phosphatase 5                                                        −1.7
                                             *MAP3K6*      Mitogen-activated protein kinase kinase kinase 6                                      −2.3
                                             *PLA2G3*      Phospholipase A2, group III                                                           −3.6
   Cytokine--cytokine receptor interaction   *TNFRSF25*    Tumor necrosis factor receptor superfamily member 25 isoform 1 precursor              3.2
                                             *CX3CR1*      Chemokine (C-X3-C motif) receptor 1                                                   1.8
                                             *CCR5*        Chemokine (C-C motif) receptor 5                                                      1.6
                                             *IL12RB1*     Interleukin 12 receptor, beta 1                                                       −1.6
                                             *LTα*         Lymphotoxin A                                                                         −1.6
                                             *CCL17*       Chemokine (C-C motif) ligand 17                                                       −2.1

Abbreviations*:* DEG, differentially expressed gene; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase.

In oxidative phosphorylation, *ATP60C* was increased (1.35-fold, *P* = 0.0133) whereas *COX7B* was decreased (−1.96-fold, *P* = 0.0136) significantly in a similar pattern as transcriptome data at acute phase compared to sham control ([Fig. 2A](#fig2-0963689717715822){ref-type="fig"}). Western blot also exhibited same pattern as qRT-PCR: *ATP6V0C* (1.6-fold, *P* = 0.0013) and *COX7B* (0.5247-fold, *P* = 0.0045; [Fig. 2B](#fig2-0963689717715822){ref-type="fig"}, [C](#fig2-0963689717715822){ref-type="fig"}).

![Validation using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and Western blot at acute phase. (A) RNA sequencing, *RNA-Seq*; *ATP6V0*C is significantly upregulated and *COX7B*, Cytochrome c oxidase subunit VIIb is significantly downregulated in oxidative phosphorylation pathway at acute phase (*n* = 3 per group; \**P* \< 0.05). The relative expression of target genes from qRT-PCR were calculated using 2^−ΔΔCT^ method. All results were expressed as means ± standard error of the mean. (B) Western blot analysis was performed using antibodies against *ATP6V0C*, *COX7B,* and *ACTIN* (as control). (C) Comparison of relative protein expression from the brain between sham control and 3 h post--spinal cord injury verified by Western blot. \*\**P* \< 0.01.](10.1177_0963689717715822-fig2){#fig2-0963689717715822}

At subacute phase, compared to sham control, 3 upregulated genes (*TNFRSF25, CCR5*, and *CCR6*) and 3 downregulated genes (*TNFRSF25, CCR5*, and *CCR6*) were identified in cytokine--cytokine receptor interaction, 3 upregulated genes (*GNG11, CCR5,* and *CCR6*) and 2 downregulated genes (*CCL17, NFKBIA*) were identified in chemokine signaling pathway, and there were 4 upregulated genes (*HSPA1AB, HSPA5, CALR,* and *PDIA3*) and 1 downregulated gene (*H2-L*) in antigen processing and presentation. These genes were determined by qRT-PCR as follows: *TNFRSF25* (5.37-fold, *P* = 0.0284), *HSPA1AB* (4.84-fold, *P* = 0.0284), *CCR6* (3.15-fold, *P* = 0.0133), *CCR5* (2.42-fold, *P* = 0.0133), *HSPA5* (2.36-fold, *P* = 0.0284), *GNG11* (2.01-fold, *P* = 0.0133), *CALR* (1.57-fold, *P* = 0.0284), *PDIA3* (1.45-fold, *P* = 0.0136), *HGF* (−1.43-fold, *P* = 0.0133), *H2-L* (−1.60-fold, *P* = 0.0136), *NFKBIA* (−1.80-fold, *P* = 0.0136), *CCL17* (−2.03-fold, *P* = 0.0136), and *IL12RB1* (−3.10-fold, *P* = 0.0167; [Fig. 3A](#fig3-0963689717715822){ref-type="fig"}). Western blot showed that *TNFRSF25* (1.49-fold, *P* = 0.0044), *HSPA1AB* (1.67-fold, *P* = 0.0096), and *HSPA5* (1.43-fold, *P* = 0.0359) proteins were increased, although *NFKBIA* was decreased (0.049-fold, *P* = 0.0059) significantly at subacute phase compared to sham control ([Fig. 3B](#fig3-0963689717715822){ref-type="fig"}, [C](#fig3-0963689717715822){ref-type="fig"}).

![Validation using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and Western blot at subacute phase. (A) *TNFRSF25, HSPA1AB, CCR6, CCR5, HSPA5, GNG11, CALR,* and *PDIA3* are significantly upregulated and *HGF, H2-L, NFKBIA, CCL17,* and *IL12RB1* are significantly downregulated at subacute phase. These genes are involved in cytokine--cytokine receptor interaction, chemokine signaling pathway, and antigen processing and presentation (*n* = 3 per group; \**P* \< 0.05). The relative expression of target genes from qRT-PCR was calculated using 2^−ΔΔCT^ method. All results were expressed as means ± standard error of the mean. (B) Western blot analysis was performed using antibodies against *TNFRSF25, HSPA1AB, HSPA5, NFKBIA,* and *ACTIN* (as control). (C) Comparison of relative protein expression from the brain between sham control and 2 wk post--spinal cord injury verified by Western blot. RNA sequencing, *RNA-Seq*; ATP6V0C, ATPase, H+ transporting V0 subunit C; COX7B, TNFRSF25, Tumor necrosis factor receptor superfamily member 25 isoform 1 precursor; CCR5, Chemokine (C-C motif) receptor 5; CCR6, Chemokine (C-C motif) receptor 6; IL12RB1, Interleukin 12 receptor, beta 1; CCL17, Chemokine (C-C motif) ligand 17; GNG11, Guanine nucleotide binding protein (G protein), gamma 11; NFKBIA, Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha; HSPA1AB, Heat shock protein 1AB; HSPA5, Heat shock protein 5; CALR, Calreticulin; PDIA3, Protein disulfide isomerase associated 3; H2-L, Histocompatibility 2, D region locus L. \**P* \< 0.05. \*\**P* \< 0.01.](10.1177_0963689717715822-fig3){#fig3-0963689717715822}

At subacute phase, compared to acute phase, there were 3 enriched KEGG pathways such as antigen processing and presentation, MAPK signaling pathway, and cytokine--cytokine receptor interaction. Two upregulated genes (*HSPA1AB* and *HSPA5*) and three downregulated genes (*H2-T22, LTA,* and *H2-K1*) were detected in antigen processing and presentation. Six upregulated genes (*HSPA1AB, HSPB1, JMJD7, FGFR2, RASGRP3*, and *DDIT3*) and three downregulated genes (*DUSP5, MAP3K6*, and *PLA2G3*) were detected in MAPK signaling pathway. Finally, there were 3 upregulated genes (*DUSP5, MAP3K6, and PLA2G3*) and 3 downregulated genes (*IL12RB1, LTA*, and *CCL17*) in cytokine--cytokine receptor interaction. These genes were determined by qRT-PCR as follows: *TNFRSF25* (5.79-fold, *P* = 0.0284), *HSPA1AB* (5.09-fold, *P* = 0.0284), *HSPB1* (2.12-fold, *P* = 0.0284), *CCR5* (1.99-fold, *P* = 0.0136), *HSPA5* (1.94-fold, *P* = 0.0133), *DDIT3* (1.76-fold, *P* = 0.0284), *FGFR2* (1.69-fold, *P* = 0.0284), *CX3CR1* (1.62-fold, *P* = 0.0133), *RASGRP3* (1.55-fold, *P* = 0.0284), *JMJD7* (1.43-fold, *P* = 0.0133), *H2-T22* (−1.60-fold, *P* = 0.0136), *DUSP5* (−1.61-fold, *P* = 0.0133), *CCL17* (−1.97-fold, *P* = 0.0133), *H2-K1* (−2.58-fold, *P* = 0.0177), *LTα* (−3.81-fold, *P* = 0.0133), *IL12RB1* (−4.7-fold, *P* = 0.0295), *PLA2G3* (−4.80-fold, *P* = 0.0152), and *MAP3K6* (−6.67-fold, *P* = 0.0133; [Fig. 4A](#fig4-0963689717715822){ref-type="fig"}). According to Western blot results, *TNFRSF25* (2.48-fold, *P* = 0.0004), *HSPA1AB* (1.98-fold, *P* = 0.0004), and *HSPA5* (1.45-fold, *P* = 0.0196) proteins were increased significantly at subacute phase compared to acute phase ([Fig. 4B](#fig4-0963689717715822){ref-type="fig"}, [C](#fig4-0963689717715822){ref-type="fig"}). Validated enriched KEGG pathways were shown in [Fig. 5](#fig5-0963689717715822){ref-type="fig"}.

![Validation using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and Western blot at subacute phase compared to acute phase. (A) *TNFRSF25, HSPA1AB, HSPB1, CCR5, HSPA5, DDIT3, FGFR2, CX3CR1, RASGRP3,* and *JMJD7* are significantly upregulated and *H2-T22, DUSP5, CCL17, H2-K1, LTα, IL12RB1, PLA2G3,* and *MAP3K6* are significantly downregulated subacute phase. These genes are involved in cytokine--cytokine receptor interaction, chemokine signaling pathway, and antigen processing and presentation (*n* = 3 per group; \**P* \< 0.05). The relative expression of target genes from qRT-PCR were calculated using 2^−ΔΔCT^ method. All results were expressed as means ± standard error of the mean. (B) Western blot analysis was performed using antibodies against *TNFRSF25, HSPA1AB, HSPA5,* and *ACTIN* (as control). (C) Comparison of relative protein expression from the brain between 3 h post--spinal cord injury (SCI) and 2 wk post-SCI verified by Western blot. TNFRSF25, Tumor necrosis factor receptor superfamily member 25 isoform 1 precursor; CCR5, Chemokine (C-C motif) receptor 5; IL12RB1, Interleukin 12 receptor, beta 1; CCL17, Chemokine (C-C motif) ligand 17; HSPA1AB, Heat shock protein 1AB; HSPA5, Heat shock protein 5; CALR, Calreticulin; PDIA3, Protein disulfide isomerase associated 3; H2-L, Histocompatibility 2, D region locus L; H2-T22, Histocompatibility 2, T region locus 22; LTα, Lymphotoxin A; H2-K1, Histocompatibility 2, K1, K region; HSPB1, Heat shock protein 1; JMJD7, Jumonji domain containing 7; FGFR2, Fibroblast growth factor receptor 2; RASGRP3, RAS, guanyl releasing protein 3; DDIT3, DNA damage-inducible transcript 3 protein; DUSP5, Dual specificity phosphatase 5; MAP3K6, Mitogen-activated protein kinase kinase kinase 6; PLA2G3, Phospholipase A2, group III; CX3CR1, Chemokine (C-X3-C motif) receptor 1. \**P* \< 0.05, \*\*\**P* \< 0.001.](10.1177_0963689717715822-fig4){#fig4-0963689717715822}

![Illustration of the validated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. (A) Oxidative phosphorylation pathway. Red stars denote the enriched genes. (B) Cytokine--cytokine receptor interaction pathway. Orange stars denote the enriched genes at subacute phase. Red stars denote the enriched genes at subacute phase compared to acute phase. (C) Chemokine signaling pathway. Orange stars denote the enriched genes at subacute phase. (D) Antigen processing and presentation pathway. Orange stars denote the enriched genes at subacute phase. Red stars denote the enriched genes at subacute phase compared to acute phase. (E) Mitogen-activated protein kinase signaling pathway. Red stars denote the enriched genes at subacute phase compared to acute phase. These pathways mapping were provided from the KEGG pathways of Database for Annotation Visualization, and Integrated Discovery functional annotation tool (DAVID v6.7; <http://david.abcc.ncifcrf.gov/>).](10.1177_0963689717715822-fig5){#fig5-0963689717715822}

Discussion {#section15-0963689717715822}
==========

Although several studies have shown that SCI may affect brain,^[@bibr11-0963689717715822],[@bibr12-0963689717715822]^ the underlying pathophysiological mechanisms have not been completely elucidated. The main purpose of the present study is to evaluate the gene expression profiling in the brain after SCI. Based on a previous report focusing on time point post-injury in a mouse model of SCI^[@bibr30-0963689717715822]^, we systemically characterized the brain after SCI at acute phase (3 h post-injury) and subacute phase (2 wk post-injury). The different gene expressions and associated enriched KEGG pathways were analyzed and validated to elucidate the progression of pathophysiological mechanism in the brain after SCI.

In the acute phase, *ATP6V0C* was upregulated due to oxidative phosphorylation, compared to sham control, while *COX7B* was downregulated by RNA-seq, qRT-PCR ([Table 3](#table3-0963689717715822){ref-type="table"}; [Fig. 2A](#fig2-0963689717715822){ref-type="fig"}), and Western blot ([Fig. 2B](#fig2-0963689717715822){ref-type="fig"}, [C](#fig2-0963689717715822){ref-type="fig"}). Oxidative phosphorylation is an effective metabolic pathway that provides energy by adenosine triphosphate (ATP) synthesis in the mitochondria of cells.^[@bibr31-0963689717715822],[@bibr32-0963689717715822]^ There are 5 main protein complexes in the electron transport chain, which are nicotinamide adenine dinucleotide hydride (NADH) dehydrogenase (complex I), succinate dehydrogenase (complex II), cytochrome bc1 complex (complex III), cytochrome c oxidase (complex IV), and ATP synthase (complex V). The upregulation of *ATP6V0C* and downregulation of *COX7B* resulted in impaired oxidative phosphorylation, which could increase mitochondrial reactive oxygen species (ROS) production from electron transport chain complexes. The CNS has high oxygen consumption, hence particularly susceptible to ROS-induced damage.^[@bibr33-0963689717715822],[@bibr34-0963689717715822]^ Mitochondrial dysfunction and impaired oxidative phosphorylation may play an important role in the pathogenesis of brain injury after SCI, especially at acute phase.

At subacute phase, cytokine--cytokine receptor interaction (upregulation: *TNFRSF25, CCR5,* and *CCR6*; downregulation: *HGF* and *IL12RB1*), chemokine signaling pathway (upregulation: *GNG11, CCR5,* and *CCR6*; downregulation: *CCL17* and *NFKBIA*), and antigen processing and presentation pathways (upregulation: *HSPA1AB, HSPA5, CALR,* and *PDIA3*; downregulation: *H2-L*) were activated by RNA-seq ([Table 3](#table3-0963689717715822){ref-type="table"}; [Fig. 3](#fig3-0963689717715822){ref-type="fig"}). Furthermore, antigen processing and presentation (upregulation: *HSPA1AB* and *HSPA5*; downregulation: *H2-T22, LTα,* and *H2-K1*) and cytokine--cytokine receptor interaction pathways (upregulation: *TNFRSF25, CX3CR1,* and *CCR5*; downregulation: *IL12RB1, LTα,* and *CCL17*) were also elevated at subacute phase compared to acute phase ([Table 3](#table3-0963689717715822){ref-type="table"}; [Fig. 4](#fig4-0963689717715822){ref-type="fig"}).

Cytokines and chemokines are very important for CNS immune system interactions. In the nervous system, they function as neuromodulators and regulate neurodevelopment, neuroinflammation, and synaptic transmission. In the brain, cytokines and chemokines are crucial for immune response such as maintaining immunological surveillance, leukocyte traffic modulation, and other inflammatory factor recruitment.^[@bibr35-0963689717715822],[@bibr36-0963689717715822]^ *TNFRSF25* is one of the proinflammatory members, which can stimulate T lymphocyte, B lymphocyte, and antigen presenting cells.^[@bibr37-0963689717715822]^ *TNFSF25* can induce nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) via tumor necrosis factor receptor type 1--associated death domain protein (TRADD) and Tumor necrosis factor (*TNF*) receptor--associated factor 2 (*TRAF2*).^[@bibr38-0963689717715822]^ *CCR5* is one of the members of chemokine receptor family and plays an important role in the pathogenesis of brain injury and neurodegenerative disorders.^[@bibr39-0963689717715822],[@bibr40-0963689717715822]^ *CCR6* is one of the chemokine receptors that can bind to a single chemokine ligand, *CCL20*. *CCL20/CCR6* is important for the trafficking of T cells to the CNS across the choroid plexus during immune surveillance as well as neuroinflammation.^[@bibr41-0963689717715822]^ *GNG11*, membrane bound G-protein subunit, is induced by oxidative stress and may regulate cell senescence.^[@bibr42-0963689717715822]^ *CX3CR1* is a receptor of the chemokine fractalkine (*CX3CL1*). *CX3CL1/CX3CR1* axis can regulate the maintenance of the communication between neuron and microglia in health and disease.^[@bibr36-0963689717715822],[@bibr43-0963689717715822]^ Especially in the brain of mice, ischemic condition might stimulate neurons to release *CX3CL1* and microglia to express *CX3CR1*.^[@bibr44-0963689717715822]^ The interaction of *CX3CL1/CX3CR1* increased in the brain of ischemic mice. *HGF* is an angiogenic growth factor, which prevents the extension of several ischemic injuries.^[@bibr45-0963689717715822][@bibr46-0963689717715822][@bibr47-0963689717715822]--[@bibr48-0963689717715822]^ *NFKBIA* encodes *IκBα*, negative regulator of transcription factor *NF-κB*, which regulates proinflammatory cytokines, chemokines, and is also related to prosurvival and antiapoptosis.^[@bibr49-0963689717715822][@bibr50-0963689717715822]--[@bibr51-0963689717715822]^ *IL-12* receptor (*IL-12R*) has 2 subunits, *β1* and *β2*, which are required to bind IL-12 for high affinity. The signaling function of *IL-12Rβ1* has not been revealed yet, but it may be needed to maintain high affinity binding with cytokine.^[@bibr44-0963689717715822]^ *LTα*, a proinflammatory cytokine with homology to tumor necrosis factor alpha (*TNFα*), has not been investigated clearly but may contribute to inflammatory processes.^[@bibr52-0963689717715822]^ *CCL17* is a small cytokine, also known as thymus and activation regulation chemokine. *CCL17* binds and induces chemotaxis in T cells that may associate with inflammation.^[@bibr53-0963689717715822],[@bibr54-0963689717715822]^ Thus, neuroinflammation in the brain after SCI may induce activation of cytokine--cytokine receptor interaction, chemokine signaling pathway at subacute phase compared to sham control, as well as cytokine--cytokine receptor interaction also have a role at subacute phase compared to acute phase.

Antigen processing and presentation pathway was activated at subacute phase compared to sham control as follows, upregulation: *HSPA1AB, HSPA5, CALR,* and *PDIA3*; downregulation: *H2-L* ([Table 3](#table3-0963689717715822){ref-type="table"}; [Fig. 3](#fig3-0963689717715822){ref-type="fig"}), and also activated at subacute phase compared to acute phase as follows---upregulation: *HSPA1AB *and* HSPA5*; downregulation: *H2-T22, LTα,* and *H2-K1* ([Table 3](#table3-0963689717715822){ref-type="table"}; [Fig. 4](#fig4-0963689717715822){ref-type="fig"}).

Endoplasmic reticulum (ER) stress not only plays vital role in mediating ischemic neuronal cell death but also mediates pathophysiological reactions in brain injuries.^[@bibr55-0963689717715822]^ ER stress could modulate dysregulation of Major histocompatibility complex I (MHC I) peptide presentation during infected and transformed cells by cluster of differentiation 8 (CD 8) T lymphocytes.^[@bibr56-0963689717715822]^ The connection between presentation of MHC I-associated peptides and CD8 T cells is tight. MHC I peptides are primarily generated by de novo synthesis and degraded rapidly.^[@bibr56-0963689717715822][@bibr57-0963689717715822]--[@bibr58-0963689717715822]^ Following proteasomal degradation, peptides are translocated into ER. The ER responds to the accumulating unfolded proteins by activating intracellular signal transduction pathways called the unfolded protein response (UPR). UPR can regulate MHC I peptide processing, protein translocation, and degradation. Therefore, ER stress affects MHC I peptide presentation. During ER stress, dysregulation of MHC I presentation leads to impaired presentation of peptides derived from proteins.^[@bibr56-0963689717715822]^ *HSPA1AB* and *HSPA5* play multiple roles in cellular homeostasis. Their expressions are significantly increased in several types of stress conditions and lead to reduced RNA translation and enhanced the degradation of misfolded proteins.^[@bibr59-0963689717715822],[@bibr60-0963689717715822]^ *CALR*, as a modulator of the Ca^++^ balance, is located mostly in the lumen of the ER. During ER stress, *CALR* expression is upregulated and transferred to outside the cell.^[@bibr61-0963689717715822],[@bibr62-0963689717715822]^ *PDIA3*, a member of ER stress proteins, can be induced by oxidative stress conditions. *PDIA3* is mediated by redox-sensitive transcription factors, in cellular response to oxidative stress.^[@bibr63-0963689717715822],[@bibr64-0963689717715822]^ Therefore, ER stress in the brain after SCI may be induced by the activation of antigen processing and presentation at subacute phase compared to sham control and acute phase.

MAPK signaling pathway plays a vital role in ER stress, which was activated at subacute phase as follows---upregulation: *HSPA1AB, HSPB1, JMJD7, FGFR2, RASGRP3,* and *DDIT3*; downregulation: *DUSP5, MAP3K6,* and *PLA2G3* ([Table 3](#table3-0963689717715822){ref-type="table"}; [Fig. 4](#fig4-0963689717715822){ref-type="fig"}). MAPK signaling pathway is activated in response to ER stress and UPR.^[@bibr65-0963689717715822]^ Particularly, Heat shock proteins (HSPs) are constitutively expressed in certain cell types and are also induced upon exposure of cells to elevated temperatures and other cell stress environments.^[@bibr66-0963689717715822]^ In MAPK pathway, phosphorylated HSPB1 plays a key role in the induction of several genes related to inflammatory response. The signaling components of the Fibroblast growth factor (FGF) family interact with tyrosine kinase fibroblast growth factor receptors (FGFRs). FGFRs activation leads to phosphorylation of specific tyrosine residues, mediates interaction of cytosolic adaptor proteins, and regulates several intracellular signaling pathways, such as RAS-MAPK, phosphatidylinositol 3-kinase (PI3K)-AKT, phospholipase C gamma (PLC gamma), and signal transducer and activator of transcription (STAT).^[@bibr67-0963689717715822]^ Activation of *FGFR2* may regulate MAPK signaling. In response to ER stress, MAPK signaling pathway is activated in the brain after SCI at subacute phase compared to acute phase.

Taken together, we focused on the brain after SCI pathophysiological events. Our study suggested that gene expression change plays an important role in the pathophysiological process of the injury, and SCI also affects brain injury. In addition, individual genes, which involved in enriched KEGG pathways, will be considered reliable molecular markers in the brain after cell-based therapy in SCI. In further study, investigation should be extended to provide neurobiological mechanism for association between brain and spinal cord. This gene expression change may contribute to new mechanisms and therapeutic targets for CNS disorders.

Conclusions {#section16-0963689717715822}
===========

Our study provided gene expression patterns in the brain after SCI in pathophysiological processes (acute phase and subacute phase). In the brain after SCI, mitochondria dysfunction occurred at acute phase, followed by inflammatory response and ER stress aroused at subacute phase. Finally, these stress environments led to the activation of MAPK signaling pathway at subacute phase ([Fig. 6](#fig6-0963689717715822){ref-type="fig"}). These pathophysiological mechanisms have already been reported in SCI.^[@bibr68-0963689717715822][@bibr69-0963689717715822]--[@bibr70-0963689717715822]^ Our results emphasized that SCI is closely associated with brain injuries. Hence, these mechanisms may provide not only a link between SCI and brain injury but also valuable reference data for understanding gene expression patterns at acute phase and subacute phase.

![Summary of transcriptomic changes in the brain after spinal cord injury (SCI). In the brain after SCI, A; mitochondria function impairs at acute phase (3 h post-injury), B; while inflammatory response and endoplasmic reticulum (ER) stress occur at subacute phase (2 wk post-injury). These cascades lead to the activation of mitogen-activated protein kinase (MAPK) signaling pathway. These mechanisms suggest that SCI and brain injury are closely associated with each other.](10.1177_0963689717715822-fig6){#fig6-0963689717715822}

**Ethical Approval:** This study was approved by the Institutional Animal Care and Use Committee (IACUC) of Yonsei University Health System.

**Statement of Informed Consent:** There are no human subjects in this article and informed consent is not applicable.

**Declaration of Conflicting Interests:** The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding:** The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from the National Research Foundation (NRF-2014R1A2A1A11052042, NRF-2015M3A9B4067068), the Ministry of Science and Technology, Republic of Korea, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI; HI14C1234, HI16C1012), Ministry of Health & Welfare, Republic of Korea.
